STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $278,357 | +27.6% | 26,186 | 0.0% | 0.00% | – |
| Q1 2023 | $218,129 | -9.8% | 26,186 | 0.0% | 0.00% | – |
| Q4 2022 | $241,697 | -29.1% | 26,186 | 0.0% | 0.00% | – |
| Q3 2022 | $341,000 | -25.7% | 26,186 | -24.6% | 0.00% | -100.0% |
| Q2 2022 | $459,000 | -37.2% | 34,714 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $731,000 | -12.2% | 34,714 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $833,000 | +12.4% | 34,714 | +19.2% | 0.00% | 0.0% |
| Q3 2021 | $741,000 | -11.2% | 29,114 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $834,000 | -42.0% | 29,114 | -21.3% | 0.00% | -50.0% |
| Q1 2021 | $1,438,000 | -25.9% | 37,014 | +18.1% | 0.00% | 0.0% |
| Q4 2020 | $1,941,000 | +160.2% | 31,341 | +40.7% | 0.00% | +100.0% |
| Q3 2020 | $746,000 | +40.5% | 22,279 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $531,000 | +4.1% | 22,279 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $510,000 | -9.4% | 22,279 | +12.1% | 0.00% | 0.0% |
| Q4 2019 | $563,000 | +31.9% | 19,879 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $427,000 | – | 19,879 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |